Atria Wealth Solutions Inc. Has $6.52 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Atria Wealth Solutions Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,495 shares of the biopharmaceutical company’s stock after buying an additional 338 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Gilead Sciences were worth $6,521,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Altfest L J & Co. Inc. acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $210,000. Federated Hermes Inc. boosted its holdings in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after buying an additional 175,925 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $74,000. Abundance Wealth Counselors acquired a new position in shares of Gilead Sciences in the third quarter valued at approximately $1,881,000. Finally, HTLF Bank acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $253,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GILD. Mizuho cut their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Oppenheimer reissued an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Cantor Fitzgerald cut their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Friday. Finally, StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and a consensus price target of $84.57.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $0.57 during mid-day trading on Friday, reaching $64.70. 2,021,575 shares of the company were exchanged, compared to its average volume of 7,345,926. The company has a fifty day simple moving average of $71.40 and a 200-day simple moving average of $76.32. Gilead Sciences, Inc. has a 12 month low of $64.69 and a 12 month high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm has a market cap of $80.56 billion, a PE ratio of 14.50, a PEG ratio of 1.20 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter last year, the company posted $1.37 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.2 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.76%. Gilead Sciences’s payout ratio is presently 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.